Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Insulin Resistance Following ADT for Prostate CA
NCT04658849 · St. Louis University · EARLY_PHASE1 · withdrawn · last registry update 2023-05-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “End of grant funding” | – | Registry record, St. Louis University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPARG within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-05-08Also stopped (terminated): University Hospital Regensburg, low-dose Azacitidine + Pioglitazone (NCT02942758)
- 2024-03-19Results posted on the registry: Biogen, Bardoxolone methyl (NCT03749447)
- 2024-02-07Phase 3 first posted: The University of Texas Health Science Center at San Antonio, Tirzepatide + Pioglitazone (NCT06246799)
- 2023-12-19Phase 3 first posted: Faes Farma, S.A., Mesalazine (NCT06176560)
- 2023-10-30Phase 3 first posted: University of Basrah, Insulin Glargine 100 UNT/ML Pen Injector [Lantus] + Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg (NCT06107153)
- 2023-10-27Also stopped (terminated): Biogen, 20 mg bardoxolone methyl + Placebo (NCT01500798)
- 2023-10-12Results posted on the registry: Biogen, Bardoxolone methyl (NCT03068130)
- 2023-10-11Results posted on the registry: Biogen, Placebo Oral Capsule + Bardoxolone Methyl (NCT03019185)
- 2023-09-26Also stopped (terminated): Kyowa Kirin Co., Ltd., Bardoxolone methyl + Placebo (NCT03550443)
- 2023-08-15Also stopped (withdrawn): State University of New York at Buffalo, Pioglitazone 30 mg + Placebo (NCT05098327)
- 2023-08-14Phase 3 first posted: Mostafa Bahaa, Mesalamine + Nifuroxazide (NCT05988528)
- 2023-08-14Phase 3 first posted: Mostafa Bahaa, Mesalamine + Dapagliflozin 10mg Tab (NCT05986136)
- 2023-07-14Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Pioglitazone (ACTOS®) + Placebo of Pioglitazone (NCT05946564)
- 2023-06-23Also stopped (withdrawn): St. Louis University, Pioglitazone 30 mg + placebo tablet (NCT04995978)
- 2023-05-19Results posted on the registry: Biogen, Placebo capsules + Bardoxolone methyl capsules (NCT02657356)
- 2023-04-19Phase 3 first posted: Minoryx Therapeutics, S.L., Leriglitazone + Placebo (NCT05819866)
- 2023-03-21Also stopped (terminated): University of Chicago, depot leuprolide plus estrogen/progestin replacement + pioglitazone (NCT00203996)
- 2023-03-08Results posted on the registry: National Cancer Institute (NCI), Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet (NCT02917629)
- 2023-03-08Also stopped (terminated): National Cancer Institute (NCI), Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet (NCT02917629)
- 2023-03-03Phase 3 first posted: Tanta University, Mesalamine + Fenofibrate 160mg (NCT05753267)
- 2023-02-24Results posted on the registry: University of Guadalajara, Berberine + Bezafibrate (NCT02548832)
- 2023-02-14Also stopped (terminated): Emory University, Pioglitazone (NCT03060772)
- 2023-02-08Also stopped (suspended): Zydus Therapeutics Inc., Saroglitazar Magnesium 1 mg + Saroglitazar Magnesium 2 mg (NCT03097107)
- 2023-02-01Also stopped (withdrawn): Xijing Hospital of Digestive Diseases, berberine + regular treatment (NCT02962245)
- 2023-02-01Also stopped (withdrawn): Xijing Hospital of Digestive Diseases, Mesalazine Sustained-Release Tablets + Riboflavin Sodium Phosphate Injection (NCT02769494)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision